Department of Thoracic Surgery, Akita Red Cross Hospital, Akita, Japan.
Department of Respiratory Medicine, Akita Red Cross Hospital, Akita, Japan.
Thorac Cancer. 2018 Apr;9(4):495-497. doi: 10.1111/1759-7714.12592. Epub 2018 Feb 8.
The options for lung cancer treatment have increased due to the development of immune checkpoint inhibitors, but there has been no report of inoperable cases whereby the treatment effects rendered the case operable, an operation was subsequently performed, and histological assessment of the surgical specimen was carried out. Here, we report a 67-year-old man who was given pembrolizumab for T3N0 lung squamous cell carcinoma suspected of pericardial infiltration and judged inoperable. Treatment effect was evaluated after four courses. Computed tomography indicated a partial response, and operability was feasible. Therefore, thoracoscopic left upper lobectomy was performed after six courses of pembrolizumab, and histological assessment of the treatment effect was determined to be Ef 3, a complete response. The postoperative course was uneventful and he was discharged on the third postoperative day. We encountered a case that could be surgically treated after pembrolizumab administration. This treatment was safe and effective for advanced lung cancer.
由于免疫检查点抑制剂的发展，肺癌的治疗选择有所增加，但尚无不可手术病例的报告，即治疗效果使病例可手术，随后进行手术，并对手术标本进行组织学评估。在这里，我们报告了一例 67 岁男性，因怀疑心包浸润而给予 pembrolizumab 治疗 T3N0 肺鳞癌，被判断为不可手术。在四个疗程后评估治疗效果。计算机断层扫描显示部分缓解，且可手术。因此，在六个疗程 pembrolizumab 治疗后进行了胸腔镜左肺上叶切除术，治疗效果的组织学评估为 Ef 3，完全缓解。术后过程顺利，他在术后第三天出院。我们遇到了一例在 pembrolizumab 给药后可手术治疗的病例。这种治疗对晚期肺癌是安全有效的。
